前言一年一度的肿瘤领域盛会——2024年欧洲肿瘤内科学会亚洲年会（ESMO ...

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high incidence ...

It offers a non-invasive approach and has broad clinical relevance in cancer management. This comprehensive review primarily ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced ...

Hepatocellular carcinoma (HCC) is one of the most fatal malignancies. Epigenetic mechanisms have revealed that noncoding RNAs ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma ...

Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the ...

159 reported "abnormal liver function tests," which may include hepatocellular or cholestatic abnormalities or both. [15] ...

The following is a summary of the study "Clinical study on conversion therapy of hepatocellular carcinoma - summary and ...